INTRODUCTION: It is called as heart failure with reduced ejection (HFrEF) while ejection fraction (EF) is lower than 40%. Patients with EF=40-50% is called as heart failure with mid-range ejection fraction (HFmrEF) which is considered as a subgroup of heart failure with preserved ejection fraction (HFpEF) rather than HFrEF. Angiostatin inhibits angiogenesis and the proliferation of mesenchymal stem cells and there are limited studies about angiostatin in HF patients in the literature. Many studies have focused on the effect of angiostatin on endothelial cell apoptosis. By this study, we aimed to evaluate the angiostatin levels in systolic HF patients with chronic kidney disease (CKD).
METHODS: A total of 69 people consisting of patients with a diagnosis of systolic HF with CKD (n = 29) and healthy (n = 40) subjects were included the current study. After obtaining blood samples, we evaluated serum angiostatin, plasma N-terminal Pro-BNP, creatinine, and transthoracic echocardiography was performed.
RESULTS: The angiostatin level of patient group was significantly higher than the control group (163 (48-336); 58,14 (18,1-167); p=0.02; respectively). Average angiostatin level of HF patients receiving beta blocker therapy was significantly higher than the HF patients without beta-blocker (105,3 (50,7-220,7); 70,4 (35-224); p = 0.02; respectively).
DISCUSSION AND CONCLUSION: About this topic, our study is first. Angiostatin may be an important marker in systolic HF patients with CKD. Use of beta-blocker may inhibit angiogenesis and induce apoptosis in HF patients with CKD. Further studies are required on this subject.